Insights into Krabbe disease from structures of galactocerebrosidase. 2011

Janet E Deane, and Stephen C Graham, and Nee Na Kim, and Penelope E Stein, and Rosamund McNair, and M Begoña Cachón-González, and Timothy M Cox, and Randy J Read
Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0XY, United Kingdom. jed55@cam.ac.uk

Krabbe disease is a devastating neurodegenerative disease characterized by widespread demyelination that is caused by defects in the enzyme galactocerebrosidase (GALC). Disease-causing mutations have been identified throughout the GALC gene. However, a molecular understanding of the effect of these mutations has been hampered by the lack of structural data for this enzyme. Here we present the crystal structures of GALC and the GALC-product complex, revealing a novel domain architecture with a previously uncharacterized lectin domain not observed in other hydrolases. All three domains of GALC contribute residues to the substrate-binding pocket, and disease-causing mutations are widely distributed throughout the protein. Our structures provide an essential insight into the diverse effects of pathogenic mutations on GALC function in human Krabbe variants and a compelling explanation for the severity of many mutations associated with fatal infantile disease. The localization of disease-associated mutations in the structure of GALC will facilitate identification of those patients that would be responsive to pharmacological chaperone therapies. Furthermore, our structure provides the atomic framework for the design of such drugs.

UI MeSH Term Description Entries
D007965 Leukodystrophy, Globoid Cell An autosomal recessive metabolic disorder caused by a deficiency of GALACTOSYLCERAMIDASE leading to intralysosomal accumulation of galactolipids such as GALACTOSYLCERAMIDES and PSYCHOSINE. It is characterized by demyelination associated with large multinucleated globoid cells, predominantly involving the white matter of the central nervous system. The loss of MYELIN disrupts normal conduction of nerve impulses. Diffuse Globoid Body Sclerosis,Galactosylceramidase Deficiency Disease,Krabbe Disease,Classic Globoid Cell Leukodystrophy,Early-Onset Globoid Cell Leukodystrophy,GALC Deficiency,Galactocerebrosidase Deficiency,Galactosylceramide Lipidosis,Galactosylceramide beta-Galactosidase Deficiency,Galactosylceramide-beta-Galactosidase Deficiency Disease,Galactosylcerebrosidase Deficiency,Galactosylsphingosine Lipidosis,Globoid Body Sclerosis, Diffuse,Globoid Cell Leukodystrophy,Globoid Cell Leukoencephalopathy,Globoid Leukodystrophy,Infantile Globoid Cell Leukodystrophy,Krabbe Leukodystrophy,Krabbe's Disease,Krabbe's Leukodystrophy,Late-Onset Globoid Cell Leukodystrophy,Leukodystrophy, Globoid Cell, Classic,Leukodystrophy, Globoid Cell, Early-Onset,Leukodystrophy, Globoid Cell, Infantile,Leukodystrophy, Globoid Cell, Late-Onset,Psychosine Lipidosis,Cell Leukodystrophies, Globoid,Cell Leukodystrophy, Globoid,Cell Leukoencephalopathies, Globoid,Cell Leukoencephalopathy, Globoid,Deficiencies, GALC,Deficiencies, Galactocerebrosidase,Deficiencies, Galactosylceramide beta-Galactosidase,Deficiency Disease, Galactosylceramidase,Deficiency Disease, Galactosylceramide-beta-Galactosidase,Deficiency Diseases, Galactosylceramidase,Deficiency Diseases, Galactosylceramide-beta-Galactosidase,Deficiency, GALC,Deficiency, Galactocerebrosidase,Deficiency, Galactosylceramide beta-Galactosidase,Disease, Galactosylceramidase Deficiency,Disease, Galactosylceramide-beta-Galactosidase Deficiency,Diseases, Galactosylceramidase Deficiency,Diseases, Galactosylceramide-beta-Galactosidase Deficiency,Early Onset Globoid Cell Leukodystrophy,GALC Deficiencies,Galactocerebrosidase Deficiencies,Galactosylceramidase Deficiency Diseases,Galactosylceramide beta Galactosidase Deficiency,Galactosylceramide beta Galactosidase Deficiency Disease,Galactosylceramide beta-Galactosidase Deficiencies,Galactosylceramide-beta-Galactosidase Deficiency Diseases,Globoid Cell Leukodystrophies,Globoid Cell Leukoencephalopathies,Globoid Leukodystrophies,Krabbes Disease,Krabbes Leukodystrophy,Late Onset Globoid Cell Leukodystrophy,Leukodystrophies, Globoid,Leukodystrophies, Globoid Cell,Leukodystrophy, Globoid,Leukodystrophy, Krabbe,Leukodystrophy, Krabbe's,Leukoencephalopathies, Globoid Cell,Leukoencephalopathy, Globoid Cell,beta-Galactosidase Deficiencies, Galactosylceramide,beta-Galactosidase Deficiency, Galactosylceramide
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D005698 Galactosylceramidase An enzyme that hydrolyzes galactose from ceramide monohexosides. Deficiency of this enzyme may cause globoid cell leukodystrophy (LEUKODYSTROPHY, GLOBOID CELL). EC 3.2.1.46. Galactocerebrosidase,Galactosylceramide Galactosidase,Galactosylceramide beta-Galactosidase,Galactosylcerebroside beta-Galactosidase,Galactosidase, Galactosylceramide,beta-Galactosidase, Galactosylceramide,beta-Galactosidase, Galactosylcerebroside
D005699 Galactosylceramides Cerebrosides which contain as their polar head group a galactose moiety bound in glycosidic linkage to the hydroxyl group of ceramide. Their accumulation in tissue, due to a defect in beta-galactosidase, is the cause of galactosylceramide lipidosis or globoid cell leukodystrophy. Galactocerebrosides,Galactosyl Ceramide,Galactosyl Ceramides,Galactosylceramide,Ceramide, Galactosyl,Ceramides, Galactosyl
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D017433 Protein Structure, Secondary The level of protein structure in which regular hydrogen-bond interactions within contiguous stretches of polypeptide chain give rise to ALPHA-HELICES; BETA-STRANDS (which align to form BETA-SHEETS), or other types of coils. This is the first folding level of protein conformation. Secondary Protein Structure,Protein Structures, Secondary,Secondary Protein Structures,Structure, Secondary Protein,Structures, Secondary Protein

Related Publications

Janet E Deane, and Stephen C Graham, and Nee Na Kim, and Penelope E Stein, and Rosamund McNair, and M Begoña Cachón-González, and Timothy M Cox, and Randy J Read
November 2012, Pediatric neurology,
Janet E Deane, and Stephen C Graham, and Nee Na Kim, and Penelope E Stein, and Rosamund McNair, and M Begoña Cachón-González, and Timothy M Cox, and Randy J Read
June 2016, Pediatric endocrinology reviews : PER,
Janet E Deane, and Stephen C Graham, and Nee Na Kim, and Penelope E Stein, and Rosamund McNair, and M Begoña Cachón-González, and Timothy M Cox, and Randy J Read
September 2011, Proceedings of the National Academy of Sciences of the United States of America,
Janet E Deane, and Stephen C Graham, and Nee Na Kim, and Penelope E Stein, and Rosamund McNair, and M Begoña Cachón-González, and Timothy M Cox, and Randy J Read
January 1994, Biochemical and biophysical research communications,
Janet E Deane, and Stephen C Graham, and Nee Na Kim, and Penelope E Stein, and Rosamund McNair, and M Begoña Cachón-González, and Timothy M Cox, and Randy J Read
August 2014, Molecular genetics and metabolism,
Janet E Deane, and Stephen C Graham, and Nee Na Kim, and Penelope E Stein, and Rosamund McNair, and M Begoña Cachón-González, and Timothy M Cox, and Randy J Read
October 1998, Laboratory animal science,
Janet E Deane, and Stephen C Graham, and Nee Na Kim, and Penelope E Stein, and Rosamund McNair, and M Begoña Cachón-González, and Timothy M Cox, and Randy J Read
January 1988, Voprosy meditsinskoi khimii,
Janet E Deane, and Stephen C Graham, and Nee Na Kim, and Penelope E Stein, and Rosamund McNair, and M Begoña Cachón-González, and Timothy M Cox, and Randy J Read
August 2021, Clinica chimica acta; international journal of clinical chemistry,
Janet E Deane, and Stephen C Graham, and Nee Na Kim, and Penelope E Stein, and Rosamund McNair, and M Begoña Cachón-González, and Timothy M Cox, and Randy J Read
April 2022, The international journal of biochemistry & cell biology,
Janet E Deane, and Stephen C Graham, and Nee Na Kim, and Penelope E Stein, and Rosamund McNair, and M Begoña Cachón-González, and Timothy M Cox, and Randy J Read
January 2005, Journal of inherited metabolic disease,
Copied contents to your clipboard!